

CONTRACEPTION

AUTHOR INDEX

Volume 43

January to June 1991

- Adoni, A., 77
Albert, A.E., 167
Albring, M., 101
Andersch, B., 111
Andrade, A.T.L., 241
Ansari, A.S., 187, 485
Ansbacker, R., 139
Antúnez, O., 45
Apelo, R., 33
Aravena, R., 335
Atsma, W.J., 23
Back, D.J., 305, 317
Barcellona, P.S., 485
Baudhuin, P., 387
Belsey, E.M., 241, 361,
 375, 387, 401
Ben Chetrit, A., 77
Bhaduri, A.P., 507
Bhat, N., 507
Boeck, L., 45
Bordon, R., 423
Brill, K., 101
Brinton, L.A., 581
Brosents, I., 361, 375, 387
Bunce, S., 33
Buytaert, Ph., 413
Cárdenas, H., 335
Carta, Q., 423
Casado, M.E., 335
Cerza, S., 251
Chakraborty, S., 273
Chi, I-c, 33
Chretien, F.C., 55
Cornillie, F., 361, 387
Courtay, P.J., 387
Croxatto, H.B., 335
Croxall, J.D., 401
Csemiczky, G., 149
Custo, C., 251
d'Arcangues, C., 361, 401
Díaz, S., 335
Díaz-Sánchez, V., 45
Dibbelt, L., 1
Diczfalusy, E., 201
Donovan, B., 177
Dubois, R., 55
Dwivedi, A., 507
Elder, M., 129, 361, 401
Elstein, M., 129
Eneroth, P., 447
Fang, R-Y, 287
Farr, G., 229
Fioretti, P., 23
Fruzzetti, F., 23
Gates, D., 33
Gennarelli, G.L., 423
Gerofit, J., 177
Goldenberg, R.L., 325
Goodson, P., 121
Graves, W., 167
Green, A., 653
Green, S., 305
Haeberli, A., 435
Haller, H., 229
Hardy, E., 121
Hatcher, R.A., 167
Heimann, S., 1
Hourihan, H., 361, 375
Inauen, W., 435
Jackson, J.R., 325
Jayaprakash, D., 187
Johannisson, E., 361, 459
Jonsson, B., 447
Jütting, G., 1
Kamboj, V.P., 507
Kaur, J., 83, 295
Kim-Bjorklund, T., 459
Kang, R.J.B., 527
Klipping, C.O., 1
Knuppen, R., 1
Kohler, C.L., 325
Kumar, M., 187
Lammers, P., 23
Landgren, B-M, 149, 447, 459
Lasso de la Vega, J., 33
Lawson, J.P., 129
Lohiya, N.K., 187, 485
Mahato, S.B., 475
Mant, T., 317
Marbaix, E., 387
Martin, C., 317
Mehrotra, P.K., 507
Melis, G.B., 23
Merchant, P., 67
Millar, E., 317
Milne, R., 667
Milsom, I., 111
Miranda, P., 335
Mirghani, O.A., 353
Morrison, P., 317

CONTRACEPTION

- Nicoletti, I., 23
Noguera, M., 45
Norpoth, T., 101
Nuttall, I.D., 129
Orme, M., 305, 317
Pakrashi, A., 273, 475
Pal, B.C., 475
Panser, L.A., 91
Parikka-Olexik, H., 1
Patel, K.L., 67
Patel, L., 401
Perovic, M., 229
Phipps, W.R., 91
Pruthi, J.S., 83
Qian, L-j, 263
Rajalakshmi, M., 83, 295
Ramakrishnan, P.R., 83, 295
Ramos, R., 33
Randic, L., 229
Ray, H., 475
Renier, M., 413
Ricci, C., 23
Richards, J.M., Jr., 325
Rivera, R., 33
Rosenberg, L., 643
Rowe, P.J., 241
Ryan, W.G., 325
Saitto, C., 251
Saltzman, W.M., 497
Sang, G-w, 263
Schiappacasse, V., 335
Schlesselman, J.J., 557
Schnitker, J., 101
Scoccia, G., 251
Seth, M., 507
Shahani, S., 67
Sharma, D.N., 83
Sharma, K., 187
Sharma, S., 187
Shaw, S.T., Jr., 241
Shelley, G., 177
Sheppard, B., 361, 375
Shukla, R., 507
Skegg, D.C.G., 521
Souza, J.P., 241
Srivastava, R.P., 507
Stanford, J.L., 543
Straub, P.W., 435
Sullivan, M.H.F., 401
Sundell, G., 111
Taha, A.Z., 353
Tena, L.B., 497
Thomas, D.B., 597, 695
Tjia, J., 317
Trossarelli, G.F., 423
Vargas, L., 45
Vessey, M., 667
Volpec, R., 251
Ward, S., 305
Weng, L-j, 263
White, J., 361, 401
Xu, D., 263
Yang, B-z, 287
Yang, J., 161
Zhang, J-y, 263
Zhang, Y-p, 287
Zhao, Z., 161
Zheng, H-z, 263
Zhou, H-j, 287

CONTRACEPTION

SUBJECT INDEX

Volume 43

January-June, 1991

- Acacia auriculiformis triterpene saponins, effect on sperm motility, 475
Accessory gland function,
 effect of 20 Aet-1 (monkey), 83
 effect of testosterone enanthate (monkey), 83
Adenomatous hyperplasia, relation to oral contraception, 557
20 Aet-1 (testosterone-trans-4-n-butyl cyclohexyl-carboxylate)
Antifertility effect, Malvaviscus concattii flower extract (male rat), 273
Arachidonic acid metabolite production, effect of levonorgestrel, 401
Attitudes of rural mothers toward family spacing methods, 353
Benign breast disease, relation of OC use and risk of breast cancer, 597
Benzalkonium chloride, permeation through biocompatible polymers, 497
Bile and gallbladder function, effect of OC use, 667
Bioavailability,
 ethynodiol, 45
 eutectic ethynodiol-cholesterol, 45
Biochemical changes, effect of Malvaviscus concattii flower extract (male rat), 273
Biochemical effects, use of ethynodiol + desogestrel, 435
Biocompatible polymers, spermicide permeation, 497
Bioequivalence testing for therapeutic equivalence of oral contraceptives, 139
Biological profile, use of compound 85/83 (hamster, rat), 507
Biological testing, use of triterpene saponins from Acacia auriculiformis, 475
Bleeding pattern,
 use of ethynodiol + gestodene, 101, 413
 use of ethynodiol + levonorgestrel, 263
Blood coagulation, effect of ethynodiol + desogestrel, 435
Blood-subendothelium interaction, effect of ethynodiol + desogestrel, 435
Body iron stores and menstrual blood loss, 241
Brand-name vs generic oral contraceptives, bioequivalence testing, 139
Breakage of condoms during use, 167
Breakage of condoms in use, relationship of tensile testing, 177
Breast, contraceptive agents and neoplasia, 527
Breast cancer,
 relation to formulations and constituents of oral contraceptives, 597
 relative risk estimates in relation to OC use, 597
 relative risk estimates in relation to OC use in developing and developed countries, 695
Breast cancer and oral contraceptives, epidemiologic review, 597
Buserelin, alone or in combination with testosterone enanthate, antispermatic activity, reversibility and toxicity (monkey), 197

CONTRACEPTION

- Carbohydrate metabolism, effect of ethinylestradiol + gestodene, 423
CBG (corticosteroid-binding globulin)
CBG level,
 effect of ethinyl estradiol + desogestrel, 1
 effect of ethinyl estradiol + gestodene, 1
Cervical adenocarcinoma, relationship to oral contraceptives, 581
Cervical carcinoma, relative risk estimates in relation to OC use
 in developing and developed countries, 695
Cervical mucus, effect of nomegestrol acetate, 55
Cervical mucus composition, effect of various IUDs, 447
Cervical neoplasia,
 relationship to oral contraceptives, 581
 relative risk estimates in relation to OC use, 581
Cervix, contraceptive agents and neoplasia, 527
Chlorhexidine, permeation through biocompatible polymers, 497
Cholangiocarcinoma,
 relation to OC use, 643
 relative risk estimates in relation to OC use in developing
 and developed countries, 695
Clinical chemistry,
 effect of Buserelin (monkey), 187
 effect of Buserelin + testosterone enanthate (monkey), 187
Clinical experience, use of ethinylestradiol + gestodene, 101
Clinical investigations, use of tolnidamine (monkey), 485
Clinical study,
 copper-bearing Lippes Loop, 229
 Lippes Loop, 229
Coagulatory factors, effect of ethinylestradiol dose in oral
 contraceptives, 23
Colon cancer, relationship to OC use, 667
Colorectal/rectal cancer,
 relationship to OC use, 667
 relative risk estimates in relation to OC use, 667
Complaints, use of levonorgestrel-releasing intravaginal ring,
 129
Compound 85/83 (3-amino-6,7-dimethoxy-1H-pyrazolo [3,4-b]
 quinoline, effect on pregnancy (guinea pig, hamster,
 rat), 507
Condom use and breakage, 167
Condoms,
 breakage rates, 167
 motivation for use, 167
 relationship between tensile testing and breakage in use,
 177
Contraception and pregnancy outcome, 111
Contraceptive efficacy, lactational amenorrhea, 335
Contraceptive method accepted and perception of information
 received, 121
Contraceptive methods currently in use, 201
Contraceptive practices, rural village settings, 353
Contraceptive prevalence, reproductive health and future, 201
Copper-bearing Lippes Loop, clinical study, 229
Copper-containing Nova-T, effect on composition of cervical
 mucus, 447
Corpus luteum, effect of norethisterone, 459

CONTRACEPTION

- Cutaneous melanoma,
 relation to OC use, 653
 relative risk estimates in relation to OC use, 653
Cyproterone acetate, effect on epididymis and spermatozoa
 (monkey), 295
Developed vs developing countries,
 influence of OC use on risk of neoplasms, 695
 relationship between OC use and breast cancer, 597
Discontinuations,
 OC use, 111
 use of ethinyl oestradiol + gestodene, 413
 use of levonorgestrel-releasing intravaginal ring, 129
DL111-IT (3-(2-ethyl phenyl)-5-(3-methoxy phenyl)-1H-1,2,4-triazole), subsequent embryotoxic and teratogenic effects (rat), 287
Duration of OC use and relation to risk of breast cancer, 597
Effectiveness, use of ethinyl oestradiol + gestodene, 413
Efficacy, use of ethinylestradiol + gestodene, 101
Embryotoxicity, subsequent gestation after administration of DL111-IT (rat), 287
Endocrine parameters, effect of β -hCG vaccine formulations, 67
Endometrial arachidonic acid metabolites, effect of levonorgestrel, 401
Endometrial cancer,
 relative risk estimates in relation to OC use, 557
 relative risk estimates in relation to OC use in developing and developed countries, 695
Endometrial lysosomal enzymes, effect of levonorgestrel, 387
Endometrial morphology,
 effect of levonorgestrel, 361
 effect of norethisterone, 459
Endometrial vasculature, effect of levonorgestrel, 375
Endometrium,
 contraceptive agents and neoplasia, 527
 effect of norethisterone, 459
 oral contraceptives and neoplasia, 557
Environmental health and reproductive health, 201
Epididymal tubules culture system (monkey), 295
Epididymis, effect of cyproterone acetate (monkey), 295
Estrogen action, relevant to neoplasia, 527
Estrogen replacement therapy, risk of endometrial cancer, 557
Ethinylestradiol, absorption study, 45
Ethinyl estradiol + desogestrel,
 effect of deliberate omission of pill intake, 149
 effect on blood coagulation and thrombogenesis, 435
 effect on coagulatory factors, 23
 effect on SHBG and CBG levels, 1
 high and low estrogen dose, 435
 pharmacokinetic parameters for ethinyl estradiol, 1
Ethinyl estradiol + gestodene,
 clinical experience, 101
 clinical trial, 413
 effect on carbohydrate metabolism, 423
 effect on coagulatory factors, 23
 effect on SHBG and CBG levels, 1
 pharmacokinetic parameters for ethinyl estradiol, 1

CONTRACEPTION

- Ethinyl estradiol + levonorgestrel,
 clinical experience, 263
 effect of deliberate omission of pill intake, 149
 effect on coagulatory factors, 23
- Ethinylestradiol dose in oral contraceptives, effect on
 haemostatic system, 23
- Ethinyl estradiol level,
 following ethinyl estradiol + desogestrel, 1
 following ethinyl estradiol + gestodene, 1
- Ethinylestradiol-cholesterol eutectic combination, absorption
 study, 45
- Ethynelestradiol, pharmacokinetics, 305
- Ethynelestradiol + desogestrel, effect on pharmacokinetics of
 ethynylestradiol, 305
- Ethynelestradiol + gestodene, effect on pharmacokinetics of
 ethynylestradiol, 305
- Ethynelestradiol + levonorgestrel, interaction with temafloxacin,
 317
- Fallopian tube, effect of norethisterone, 459
- Family spacing attitudes and practices, 353
- Filshie clip via minilaparotomy, postpartum tubal sterilization,
 33
- Follicular growth,
 effect of ethynylestradiol + desogestrel, 149
 effect of ethynylestradiol + levonorgestrel, 149
- Gallbladder cancer, relative risk estimates in relation to OC use
 in developing and developed countries, 695
- Gallbladder-extrhepatic bile duct cancer,
 relationship to OC use, 667
 relative risk estimates in relation to OC use, 667
- Generic vs brand-name oral contraceptives, bioequivalence
 testing, 139
- Haemostatic system, effect of ethynylestradiol dose in oral
 contraceptives, 23
- β -hCG vaccines, effect on endocrine parameters, 67
- Hematologic effects, use of ethinyl estradiol + desogestrel, 435
- Hematologic indices and menstrual blood loss, effect of OC use,
 241
- Hepatocellular adenoma, relation to OC use, 643
- Hepatocellular carcinoma, relation to OC use, 643
- Hormonal levels, effect of β -hCG vaccine formulations, 67
- Hormonal profile,
 compound 85/83 (rat), 507
 effect of Malvaviscus conzattii flower extract (male rat),
 273
- Implant contraceptive, levonorgestrel, 121
- Interchangeability of oral contraceptives, generic vs brand-name
 products, 139
- Intrauterine device (IUD),
 Anticon, 251
 copper T, 251
 copper-bearing Lippes Loop, 229
 copper-containing Nova-T, 447
- Gravigard, 251

CONTRACEPTION

- levonorgestrel-releasing Nova-T, 447
- Lippes Loop D, 229
 - management following uterine perforation, 77
 - mechanical resistance assessment, 251
 - Nova-T, 251, 447
 - TCu 200, 121
- IUD (intrauterine device)
 - Kidney cancer, relationship to OC use, 667
 - Lactational amenorrhea, contraceptive efficacy, 335
 - Levonorgestrel-releasing Nova-T, effect on composition of cervical mucus, 447
 - Levonorgestrel-releasing vaginal ring,
 - effect on endometrial vascular features, 375
 - effect on endometrium, 361
 - effect on lysosomal enzymes in endometrium, 387
 - efficacy and acceptability, 129
 - prostaglandin production in endometrium, 401
 - LH-RH (luteinizing hormone-releasing hormone)
 - LH-RH agonist, Buserelin, 187
 - Lippes Loop D, clinical study, 229
- Liver, oral contraceptives and neoplasia, 527, 643
- Liver cancer,
 - relative risk estimates in relation to OC use, 643
 - relative risk estimates in relation to OC use in developing and developed countries, 695
- Luteal function,
 - effect of ethinylestradiol + desogestrel, 149
 - effect of ethinylestradiol + levonorgestrel, 149
- Lysosomal enzymes in endometrium, effect of levonorgestrel, 387
- Malvaviscus conzattii flower extract, effect on fertility (male rat), 273
- Mast cell numbers, effect of levonorgestrel, 375
- Mechanical resistance assessment, IUDs, 251
- Melanocytic nevi, relation to OC use, 653
- Melanoma,
 - effect of steroid hormones, 653
 - relation to OC use, 653
- Menstrual blood loss and body iron stores, 241
- Menstrual status postpartum, effect on probability of pregnancy, 335
- Mental health, impact of tubal sterilization, 325
- Neoplasia and oral contraceptives, 521, 527, 543, 557, 581, 597, 643, 653, 695
- Neoplasms, influence of OC use on risk in developing and developed countries, 695
- Nomegestrol acetate, effect on cervical mucus, 55
- Nonoxynol-9,
 - permeation through biocompatible polymers, 497
 - quantitative analysis in blood, 161
- Nonoxynol-9-releasing vaginal ring, 497
- Norethisterone, effect on endometrium, Fallopian tube and corpus luteum, 459
- Norplant^R, study of acceptors, 121
- Nova-T, effect on composition of cervical mucus, 447
- Nursing status, effect on probability of pregnancy, 335
- OC (oral contraceptive)
 - Omission of oral contraceptive pill intake, effect on follicular growth and luteal function, 149

CONTRACEPTION

- Oral contraceptive (OC),
ethynodiol + desogestrel, 1, 23, 149, 435
ethynodiol + gestodene, 1, 23, 101, 413, 423
ethynodiol + levonorgestrel, 317
norethisterone, 459
triphasic ethynodiol + levonorgestrel, 23, 149, 263
Oral contraceptive use, effect on pelvic inflammatory disease, 91
Oral contraceptives, bioequivalence testing for therapeutic equivalence, 139
Oral contraceptives and neoplasia, 521, 527, 543, 557, 581, 597, 643, 653, 667, 695
Organ culture of epididymal tubules (monkey), 295
Ovarian cancer,
relative risk estimates in relation to OC use, 543
relative risk estimates in relation to OC use in developing and developed countries, 695
Ovary, contraceptives and neoplasia, 527, 543
Pelvic inflammatory disease, effect of OC use, 91
Perception of information received and contraceptive method accepted, 121
Permeation through biocompatible polymers, spermicides, 497
Pharmacokinetics,
ethynodiol, 1, 45, 305
eutectic ethynodiol-cholesterol, 45
Pituitary disorders, relationship to OC use, 667
Pituitary tumours,
relationship to OC use, 667
relative risk estimates in relation to OC use, 667
Pituitary-ovarian axis, effect of β -hCG vaccine formulations, 67
Postpartum tubal sterilization, 33
Pregnancy, effect of compound 85/83 (guinea pig, hamster, rat), 507
Pregnancy history and prevalence of contraception, 111
Pregnancy probability,
according to postpartum menstrual status, 335
nursing women, 335
Pregnancy rate, postpartum tubal sterilization, 83
Progestin action, relevant to neoplasia, 527
Progestins, potency, 527
Prostaglandin production in endometrium, effect of levonorgestrel, 401
Psychosocial impact, tubal sterilization, 325
Reproductive health, 201
Resistance to mechanical fatigue, IUDs, 251
Risk factors, influence on oral contraceptives and breast cancer, 597
SHBG (sex hormone-binding globulin)
SHBG level,
effect of ethynodiol + desogestrel, 1
effect of ethynodiol + gestodene, 1
Side effects,
use of ethynodiol + desogestrel, 435
use of ethynodiol + gestodene, 101, 413
use of ethynodiol + levonorgestrel, 263
Skin neoplasia and oral contraceptives, 653
Sperm motility, effect of triterpene saponins from Acacia auriculiformis, 475

CONTRACEPTION

- Spermatogenesis,
 effect of Buserelin (monkey), 187
 effect of Buserelin + testosterone enanthate (monkey), 187
 effect of Malvaviscus concattii flower extract (rat), 271
 effect of tolnidamine (monkey), 485
- Spermatozoa,
 effect of cyproterone acetate (monkey), 295
 effect of triterpene saponins from Acacia auriculiformis,
 475
- Sterilization, tubal occlusion during postpartum hospitalization,
 33
- TCu 200, study of acceptors, 121
- Temafloxacin, interaction with ethynodiol + levonorgestrel,
 317
- Tensile testing, condoms, 177
- Teratogenicity, subsequent gestation after administration of
 DL111-IT (rat), 287
- Terminations, use of ethynodiol + levonorgestrel, 263
- Testes,
 effect of Buserelin (monkey), 187
 effect of Buserelin + testosterone enanthate (monkey), 187
 effect of tolnidamine (monkey), 485
- Testosterone enanthate, effect on accessory gland (monkey), 83
- Testosterone-trans-4-n-butyl cyclohexyl-carboxylate (20 Aet-1),
 effect on accessory gland function (monkey), 83
- Thrombogenesis, effect of ethynodiol + desogestrel, 435
- Time in woman's life OC use initiated and relation to risk of
 breast cancer, 597
- Tissue plasminogen activator, effect of levonorgestrel, 375
- Tolnidamine (1-[4-chloro-2-methylphenyl]methyl)-1H-indazole-3-
 carboxylic acid), effect on spermatogenesis (monkey),
 485
- Translocation of an IUD, management, 77
- Triphasic ethynodiol + levonorgestrel,
 clinical experience, 263
 effect of deliberate omission of pill intake, 149
 effect on coagulatory factors, 23
- Tubal sterilization,
 postpartum, 33
 psychosocial impact, 325
- Uterine corpus, oral contraceptives and neoplasia, 557
- Uterine fibroids, effect of oral contraceptives, 557
- Uterine perforation by an IUD, management, 77
- Uterine sarcoma,
 relation to oral contraception, 557
 relative risk estimates in relation to OC use in developing
 and developed countries, 695
- Vaginal ring,
 releasing levonorgestrel, 129, 361, 375, 387, 401
 releasing nonoxynol-9, 497
- Vascular subendothelium (rabbit) exposed to flowing blood, effect
 of ethynodiol + desogestrel, 435